Abstract: The performance of vector-controlled induction motor drives without a speed sensor is generally poor at very low speed. The reasons are offset and drift components in the acquired feedback ...

CEO Mihael Polymeropoulos highlighted Vanda’s entry into a new growth phase, driven by multiple commercialized products and an expanding pipeline. Fanapt prescriptions reached multi-year highs ...

Good afternoon, and welcome to the Quarter One 2025 Vanda Pharmaceuticals Incorporated Earnings Conference Call. I am Franz, and I will be the operator assisting you today. All lines have been ...

Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "Our recent new drug application filings for tradipitant and Bysanti are a testament to our productive research and ...

WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $29.5 million in its first quarter. On a per-share basis, the Washington-based company ...

Elevate your React Native applications with the power of customizable vector icons. Ideal for embellishing buttons, logos, and navigation or tab bars, these icons seamlessly integrate into your ...

Named Vector, the robotic dog was a nod to “Browne’s iconic dachshund, Hector - but fully robotic, tuxed-up, diamond-leashed, and ready to outshine me at any moment,” Patel told Vogue India. Patel ...

Vanda Pharma VNDA is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Her couture drag look featured a sharply tailored suit, a hand-embroidered Indian corset, and a scene-stealing robotic dog named Vector. Vector, adorned with a 1000-carat diamond leash, showcased ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

The facility, which was previously used by Novartis to manufacture the gene therapy Zolgensma, was picked up by BMS in early 2023 to bolster viral vector capacity for its commercial cell therapy ...